SARS-CoV-2 protein ORF3a is pathogenic in Drosophila and causes phenotypes associated with COVID-19 post-viral syndrome

Shuo Yang¹, Meijie Tian², and Aaron N. Johnson¹,³

¹Department of Developmental Biology
Washington University School of Medicine
St. Louis, MO 63110

²Genetics Branch, Oncogenomics Section
National Cancer Institute, NIH
Bethesda, MD 20892

³Author for correspondence: anjohnson@wustl.edu

Highlights
SARS-CoV-2 ORF3a is pathogenic in the nervous system.
ORF3a induces cell death, inflammation, and lysosome dysfunction.
Chloroquine protects against ORF3a induced CNS distress and lysosome dysfunction.
Summary

The Coronavirus Disease 2019 (COVID-19) pandemic has caused millions of deaths and will continue to exact incalculable tolls worldwide. While great strides have been made toward understanding and combating the mechanisms of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection, relatively little is known about the individual SARS-CoV-2 proteins that contribute to pathogenicity during infection and that cause neurological sequela after viral clearance. We used Drosophila to develop an in vivo model that characterizes mechanisms of SARS-CoV-2 pathogenicity, and found ORF3a adversely affects longevity and motor function by inducing apoptosis and inflammation in the nervous system. Chloroquine alleviated ORF3a induced phenotypes in the CNS, arguing our Drosophila model is amenable to high throughput drug screening. Our work provides novel insights into the pathogenic nature of SARS-CoV-2 in the nervous system that can be used to develop new treatment strategies for post-viral syndrome.

Main Text

SARS-CoV-2 is the causative agent of the ongoing COVID-19 pandemic, which has resulted in more than 1.5 million deaths worldwide (JHU, 2020). To stem the spread of SARS-CoV-2 and control the COVID-19 pandemic, SARS-CoV-2 research has primarily focused on understanding the mechanisms of viral infection and transmission. For example, ACE2 encodes a SARS-CoV-2 receptor, and humanized ACE2 transgenic mice have been developed to investigate the mechanisms of SARS-CoV-2 infection in vivo (Jiang et al., 2020; Kim et al., 2020; Sun et al., 2020). In contrast, relatively little is known about how specific SARS-CoV-2 proteins induce pathogenesis (Kumar et al., 2020). The high COVID-19 mortality rate suggests that proteins encoded by the SARS-CoV-2 genome are unusually virulent. After the active SARS-CoV-2 infection is cleared, or no longer detectable, a majority of recovering patients will experience post viral syndrome with indications that include neuropsychiatric symptoms and extreme fatigue lasting for several months (Mooney et al., 2020; Townsend and Dyer, 2020). As recently developed vaccines begin to control the COVID-19 pandemic, it will be critically important to identify the mechanisms by which SARS-CoV-2 proteins cause pathogenesis in order to develop treatments that mitigate the adverse affects associated with the sequela of infection.
The SARS-CoV-2 genome encodes 11 genes with 14 open reading frames (ORFs), that produce a total of 29 proteins including 16 nonstructural proteins (NSP1-NSP16), 4 structural proteins (spike protein [S], membrane protein [M], nucleocapsid protein [N], envelope protein [E]), and 9 accessory proteins (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10)(Gordon et al., 2020). The ORF3a protein is unique to coronaviruses and has been characterized in SARS-CoV, which caused the severe acute respiratory syndrome (SARS) outbreak in 2003. SARS-CoV ORF3a triggers a pathogenic inflammatory reaction through its interaction with TRAF3 that drives IL-1/IL-18 maturation and ultimately causes severe lung damage through cell pyroptosis and apoptosis (Siu et al., 2019). Moreover, SARS-CoV ORF3a induces vesicle formation and golgi fragmentation, which are prominent features observed in patient samples (Freundt et al., 2010). SARS-CoV-2 ORF3a might also be pathogenic. In vitro studies show SARS-CoV-2 ORF3a induces caspase-dependent apoptosis (Ren et al., 2020), while in silico studies argue that the ORF3a mutation rate directly correlates with SARS-CoV-2 mortality rates after infection (Majumdar and Niyogi, 2020). In addition, SARS-CoV-2 ORF3a facilitates virus replication by high jacking the autophagy machinery; despite 72.36% amino acid identity between the ORF3a proteins (Fig. S1A), SARS-CoV ORF3a does not promote viral replication (Qu et al., 2020). Although these studies suggest that SARS-CoV-2 ORF3a has unique pathogenic functions that contribute to the relatively high COVID-19 mortality rate, an in vivo model has yet to be developed that specifically interrogates the mechanisms of SARS-CoV-2 ORF3a pathogenicity.

To date, clinical treatments are not available that alleviate SARS-CoV-2 post viral syndrome. Identifying drugs that treat COVID-19 remains an urgent need, but the low availability of hACE2 transgenic mice and the requirement for P3-level infrastructure to handle SARS-CoV-2 viruses prevents a vast majority of laboratories from conducting COVID-19 research. An alternative strategy is to develop in vivo models of SARS-CoV-2 pathogenicity in which candidate drugs targeting specific viral proteins can be tested for protection against pathogenic outcomes. Promising therapeutic strategies would include compounds that block hyperinflammation and apoptosis induced by pathogenic viral proteins (Freeman and Swartz, 2020; van den Berg and Te Velde, 2020; Yap et al., 2020).

The powerful genetic tools in Drosophila have been used to identify essential mechanisms that
underlie viral infections (Hao et al., 2008; Hughes et al., 2012; Yang et al., 2018), and that contribute to viral pathogenicity (Adamson et al., 2011; Chan et al., 2009; Harsh et al., 2020). In addition, the short lifespan with easy-to-score visible phenotypes has made the fruit fly a productive *in vivo* drug screening platform (Chang et al., 2008; Dar et al., 2012; Su, 2019; Willoughby et al., 2013). Here, we report the development and characterization of an *in vivo* *Drosophila* model that assays SARS-CoV-2 proteins for tissue-specific pathogenicity and that can successfully identify drug candidates that mitigate pathogenic SARS-CoV-2 proteins.

We constructed a transgenic fly that placed ORF3a under UAS control. SARS-CoV-2 infection shows a strong tissue preference, most notably affecting the respiratory system, due to the usual route of infection and the relative abundance of ACE2 among tissues (Hikmet et al., 2020; Puelles et al., 2020). To understand if SARS-CoV-2 pathogenicity can also be tissue-specific, we used the bipartite GAL4/UAS system to express ORF3a in the central nervous system (*elav*.*Gal4*), in photoreceptors (*GMR*.*Gal4*), and in striated and smooth muscle (*Mef2*.*Gal4*). Each Gal4 driver robustly induced ORF3a expression (Fig. 1A, S1B,C), but appreciable phenotypes were only observed in flies that expressed ORF3a in the nervous system. ORF3a expression in the CNS significantly reduced lifespan (control median survival>14d, n=60; *elav>*ORF3a=5.0d, n=65; Fig 1B), impaired motor function in longitudinal climbing assays (average performance *elav>*ORF3a =1.9% of control, n>60 per genotype; Fig. 1C, S1D), and induced pronounced abdominal swelling (>90% individuals, n=65, Fig. S1E). Fewer *elav>*ORF3a adult flies eclosed than expected (49.5% of expected, n=188; Fig. 1D), suggesting ORF3a caused partial lethality during larval stages. In addition, flies that expressed ORF3a in photoreceptors showed a rough eye phenotype, which is consistent with defects in ommatidia patterning and apoptosis (100% affected, n>100; Fig. 1E). Surprisingly, ORF3a expression in muscle did not significantly affect longevity, motor function, or muscle patterning (Fig. 1F, S1F). Consistent with these results, >35% of COVID-19 patients showed neurological symptoms whereas <10% of patients showed musculoskeletal complications (Mao et al., 2020). These studies argue that ORF3a is pathogenic in only a subset of tissues, and that the CNS is particularly sensitive to ORF3a expression.

After establishing a primary infection in the respiratory system, SARS-CoV and SARS-CoV-2 can
pass the blood-brain barrier and efficiently infect the CNS (Glass et al., 2004; Meinhardt et al., 2020; Puelles et al., 2020; Zheng et al., 2020), and SARS-CoV-2 has been associated with a host of neurological symptoms including impaired consciousness, stroke, concentration problems, memory loss, dizziness and insomnia (Mao et al., 2020). Reduced lifespan and impaired motor function in \textit{elav}>\text{ORF3a} flies are phenotypes indicative of neurodegeneration (Moore et al., 2018), so we assessed apoptosis in the adult brain, and found that ORF3a induced Caspase-3 cleavage (Fig. 1G).

Neuroinflammation is often seen in COVID-19 patients, possibly via damage-associated molecular patterns (DAMPs) induced TLR4-MyD88 signaling activation (Meinhardt et al., 2020; Ren et al., 2020; Zhou et al., 2020). In \textit{Drosophila}, non-infectious sterile inflammation can be initiated when necrotic cells release DAMPs that in turn activate immunoinflammatory pathways, including the Toll and IMD pathways (Kosakamoto et al., 2020; Obata et al., 2014). We hypothesized that ORF3a elicits a sterile inflammatory response, and found that expressing ORF3a in the CNS induced Toll pathway reporter expression (fold change vs control, \textit{Drs}=10.2; Fig. 1H) and IMD reporter expression (\textit{dipt}=28.8, \textit{attA}=55.9)(Yang et al., 2019). We also assayed \textit{eiger} expression, which is a marker for Jun kinase (JNK)-mediated inflammation and apoptosis (Li et al., 2019), but \textit{eiger} expression was not significantly changed in \textit{elav}>\text{ORF3a} flies (Fig. 1I). These data demonstrate that ORF3a expression alone is sufficient to cause apoptosis, neuroinflammation, and neurotropism, and suggest ORF3a is a major virulence factor of SARS-CoV-2. Thus our ORF3a transgenic fly model recapitulates hallmarks of SARS-CoV-2 infection reported in patients and cell culture systems.

We next wanted to understand if our ORF3a model could be used to identify COVID-19 treatments. In Vero cells, lysosome deacidification is essential for virus egress, and ORF3a localized to lysosomes and caused lysosome deacidification (Ghosh et al., 2020). Toxic stress also caused lysosome deacidification in U2OS cells, and chloroquine phosphate (CQ) blocked chemically induced deacidification (Mauthe et al., 2018). Although CQ did not consistently prevent SARS-CoV-2 infections in clinical trials, the ORF3a lysosome studies suggested that CQ could prevent ORF3a-induced tropism. To understand if our fly model could respond to COVID-19 treatments, we tested the efficacy of CQ in mitigating ORF3a phenotypes. CQ treated \textit{elav}>\text{ORF3a} flies showed significantly longer lifespans.
(elav>ORF3a median survival=6d, n=121; elav>ORF3a+CQ=14d, n=79; Fig 2A), and improved motor function compared to untreated controls (average performance elav>ORF3a=1.3% of control; elav>ORF3a+CQ=9.8% of control; n>60 per genotype; Fig 2B). In addition, more CQ treated elav>ORF3a adult flies eclosed than untreated controls (treated=72.4% of expected, n=174; untreated=49.5%; Fig. 2C), suggesting CQ can suppress ORF3a induced larval lethality. These proof of principle studies largely validate our ORF3a Drosophila model as an efficient COVID-19 drug-screening platform.

At the molecular level, CQ treated elav>ORF3a flies showed reduced cleaved-caspase-3 levels (untreated FC=2.3; treated FC=1.3; Figure 2D), and reduced Toll pathway activity (Drs; FC=0.43 vs untreated; Fig. 2E) compared to untreated controls. However, IMD pathway reporters did not respond to CQ treatment (dipt=0.75, attA=0.89). One mechanism that might explain CQ specificity is that the Toll pathway is a more direct target of necrotic derived DAMPs, while the IMD pathway is not (Kosakamoto et al., 2020). A second mechanism of action for CQ could involve ORF3a-induced lysosome dysfunction. LysoTracker is a vital dye that accumulates in acidic organelles and is often used as a marker for lysosome function (Sanman et al., 2016). Similar to Vero cells, ORF3a promoted lysosome deacidification in HeLa cells (Fig. 2G,H). Strikingly, we found CQ treatment efficiently blunted ORF3a induced deacidification (Fig. 2G,H). While CQ showed no effect on inpatient survival (Geleris et al., 2020), our results argue CQ prevents apoptosis and lysosome dysfunction in ORF3a-expressing cells, and suggest CQ could ameliorate symptoms associated with SARS-CoV-2 post viral syndrome in recovering patients (Fig. 2I).

The sequelae of SARS-CoV-2 infection includes extensive neurological complications such as problems with concentration, memory loss, anxiety and depression (Halpin et al., 2020). Since the duration and severity of persistent symptoms among COVID-19 survivors is continuing to emerge, understanding and treating COVID-19 post viral syndrome will be a high healthcare priority over the next several years. Time course studies of SARS-CoV-2 infection, replication, and clearance have yet to be reported in detail, but infection parameters have been defined for the closely related SARS-CoV in mice (Glass et al., 2004). SARS-CoV was detectable in the lungs for up to 9 days after an initial nasal
inoculation, and then spread to the CNS where the virus was detectable for an additional 6 days (Glass et al., 2004). Interestingly, after infectious SARS-CoV, SARS-CoV-2, and the coronavirus Middle East Respiratory Syndrome (MERS)-CoV has been cleared, viral RNA continues to be detectable in many tissues (Glass et al., 2004; Sia et al., 2020; Widagdo et al., 2019).

Our study revealed ORF3a expression in the nervous system alone can induce cell death and neuroinflammation, suggesting ORF3a is the major virulence factor contributing to SARS-CoV-2 induced neurotropism (Figs. 1B,C). In addition, the gold standard PCR-based SARS-CoV-2 test can only assess viral load in the respiratory system. After SARS-CoV-2 is cleared from the respiratory system, and a patient tests negative, SARS-CoV-2 may continue to replicate in the CNS (Fig. 2J). The residual ORF3a may continue to trigger neurological complications associated with post viral syndrome in recovering patients, suggesting continued medical treatments are in fact required for full recovery after a 'negative' PCR-based SARS-CoV-2 test.

In summary, our results warrant further studies of SARS-CoV-2 pathogenic mechanisms as a means to treat COVID-19 post viral syndrome and identify ORF3a as a high priority target that is amenable to drug treatment (Fig. 2A,B). A future drug screen with ORF3a transgenic flies will likely reveal post-viral syndrome treatments beyond CQ.

Acknowledgments

We thank Jennifer McAdow, Yingqiu Du, and Tiffany Ou for technical support throughout the project. We also thank Mayssa Mokalled for the relentless encouragement. ANJ was supported by NIH R01AR070299.

Author Contributions

Conceptualization, S.Y., M.T. and ANJ.; Methodology and Validation, S.Y.; Formal Analysis, S.Y., M.T., and ANJ.; Investigation, S.Y. and M.T.; Resources, ANJ.; Writing-Original Draft, S.Y., M.T. and ANJ.; Supervision, ANJ.; Funding Acquisition, ANJ.

Declaration Of Interests

The authors declare no competing interests.
References


Townsend, L., and Dyer, A.H. (2020). Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. 15, e0240784.


Materials and methods

Drosophila genetics

The Gal4 stocks used to express SARS-CoV-2 ORF3a in brain, eye, and muscle included P{GAL4-elav.L} (Bloomington Stock Center, 8760), P{GAL4-ninaE.GMR} (Bloomington Stock Center, 1104), and P{Mef2-GAL4.247} (Bloomington Stock Center, 50742). Flies were maintained on standard “Bloomington recipe” media, and cultured at 25 °C under a normal light/dark cycle, unless otherwise noted.

Transgenic Flies

UAS-SARS-CoV-2-ORF3a transgenic flies were generated by PCR-mediated subcloning of the SARS-CoV-2-ORF3a coding sequence (pDONR207 SARS-CoV-2 ORF3A, #141271, Addgene) into pUASt-Attb (EcoRI/XbaI). ORF3a was amplified with Takara PrimerSTAR PCR enzyme (R050B, Takara) using the following primers:

- ORF3a-CDS-Forward: CGGAATTCATGGACCTGTTCATGAGAATCTT
- ORF3a-CDS-Reverse: GCTCTAGATTACAGTGGCACGGAGTG

Plasmid DNA was injected and targeted to a C31 integration site at 22A2 (Bloomington Stock 24481, Rainbow Transgenic Flies); stable insertions were identified by standard methods.

Immunohistochemistry and imaging

Antibodies used include anti-SARS-CoV-2-ORF3a (1:200, 101AP, FabGennix International Inc), anti-Tropomyosin (1:600, MAC141, Abcam). Embryo and brain antibody staining was performed as described (Yang et al., 2019). Tissues were imaged with a Zeiss LSM800 confocal microscope. For Drosophila eye imaging, UAS-ORF3a/TM3, Sb flies were crossed with GMR-gal4 virgin flies to direct expression of ORF3a in eyes. For wild type control, w¹¹¹⁸ flies were crossed with GMR-gal4 virgin flies. Flies were crossed at 25°C for two days; the progeny were raised at 29°C, and female adults were collected at day 3 post eclosion. Flies were frozen at ~80°C for at least 24 h and imaged with a ZEISS Axio Zoom V16 Microscope. Projected in-focus images were produced with the Montage Multifocus module of the Zen Pro Software.
Cell culture

pCMV-GFP-SARS-CoV-ORF3a was generated by recombining the SARS-CoV-2-ORF3a coding sequence (pDONR207 SARS-CoV-2 ORF3A, #141271, Addgene) into pDEST-CMV-N-EGFP (#122842, Addgene). For LysoTracker staining, Hela cells were seeded in 6-well plates with cover slips and grown to 50% confluency at 37°C with 5%CO2 in Dulbecco’s modified Eagle’s medium (12430047, Invitrogen) supplemented with 10% heat-inactivated FBS (A4766801, Invitrogen). Cells were then transfected with 1000ng DNA, using standard Lipofectamine 3000 protocols (L3000008, Invitrogen). Media was changed to DMEM with or without 10 µM chloroquine diphosphate (C6628, Sigma) 6h post transfection. 24h latter, media was removed, and cells were incubated with 10 nM LysoTracker Red DND-99 (L7528, Invitrogen) for 1h. Cells was washed with PBS for three times, mounted and imaged with a Zeiss LSM800 confocal microscope.

Western blotting

For each sample, 10 adult female heads were homogenized in 200 µl IP buffer (20 mM Hepes, pH=7.4, 150 nM NaCl, 1% NP40, 1.5 mM MgCl2, 2 mM EGTA, 10 mM NaF, 1 mM Na3VO4, 1X proteinase inhibitor), incubated on ice for 30 min and large debris was removed by 15min centrifugation (12,000Xg). Anti-cleaved-caspase 3 (#9661, Cell Signaling Technology) and anti-beta-actin (E7-C, DSHB) were used for immunoblotting. Western blots were performed by standard method using precast gels (#456-1096, BioRad), and imaged with the ChemiDoc XRS+ system (BioRad).

Longevity and motor function assays

1d old adult flies were collected and transferred to fresh food daily for both assays. For longevity analysis, the number of dead flies was recorded daily. Kaplan-Meier survival curves were generated, and statistical analysis was performed using log-rank analysis (Prism9, GraphPad Software). To assess motor function climbing assays were performed at described (Moore et al., 2018). Briefly, 15-20 flies were placed into empty vials (9.5 cm high, 1.7 cm in diameter) with flat bottoms, the flies were forced to the bottom of a vial by firmly tapping the vial against the bench surface. Eight seconds after the tap, the number of flies that climbed up the walls of a vial above the 5-cm mark was recorded as positive.
in vivo drug treatment

40mg/ml chloroquine phosphate (CQ, Sigma, C6628) was dissolved in water, and 40mg of CQ was added to each 30g of fresh fly media. Adult flies were placed on treated food at 25°C for 2d and then transferred. Progeny were cultured on CQ food from embryo stage to eclosion and transferred 24hr later to normal media (to prevent adults from sticking to wet, treated media).

Quantitative real-time RT-PCR

Total RNA was extracted with TRIzol (15596026, Invitrogen), and quantitated with a Nanodrop 2000 (Thermo Fisher). cDNA was prepared by reverse transcription with All-in-One 5X RT MasterMix (G592, Applied Biological Materials Inc) with 1000ng RNA. BlasTaq 2X qPCR MasterMix (G891, Applied Biological Materials Inc) and ABI Step One system (Applied Biosystems) were used for quantitative RT-PCR. Quantification was normalized to endogenous ribosomal protein Rp32 mRNA. RT-PCR primers included:

Diptercin-F: GGCTTATCCGATGCCCGACG
Diptercin-R: TCTGTAGGTGTAGGTGCTTCCC
Attacin-A-F: ACGCCCGGAGTGAAGGATGTT
Attacin-A-R: GGGCGATGACCAGAGATTAGCAC
Drosomycin-F: GCAGATCAAGTACTTGTTCGCCC
Drosomycin-R: CTTCGCACCAGCACTTCAGACTGG
Eiger-F: AGCGGCGTATTGAGCTGGAG
Eiger-R: TCGTCGTCCGAGCTGTCAAC

Bioinformatic and statistical analysis

Protein alignments were generated by DNAMAN 10.0 (Lynnon Biosoft). All measurement data are expressed as SEM. Comparisons of two samples were made using Student’s t test, and multiple samples by ANOVA. Survival curves were compared using the Kaplan–Meier test. P values of less than 0.05 were considered statistically significant. All statistical analyses were performed with GraphPad Prism 9 software. The sample sizes and number of replicates are indicated in the figure legends. Data collection and data analysis were routinely performed by different authors to prevent potential bias.
individuals were included in data analysis.
Figure legends

**Figure 1. ORF3a is pathogenic in the nervous system**

**A.** ORF3a localization. *elav.Gal4* and *elav>ORF3a* adult brains labeled for ORF3a (green) and DAPI (blue). ORF3a localized to cytoplasmic foci. **B.** Survival curves of *elav.Gal4* (control) and *elav>ORF3a* adult flies. *elav>ORF3a* median lifespan was significantly less than controls. n>60 flies per genotype. **C.** Longitudinal study of climbing ability. Locomotor activity was reduced in *elav>ORF3a* flies. Each data point represents percent of flies that climbed above 5 cm, averaged for 3 independent trials. See Fig. S1D. **D.** F1 adult progeny from *elav.gal4,Sb/Tb X UAS-ORF3a/Sb F0* parents. 3 phenotypic classes with an equivalent number of progeny (33.3%) were expected. *elav>ORF3a* flies were underrepresented. **E.** Micrographs of 3d adult eyes. *GMR>ORF3a* eyes were rough and disorganized. **F.** Stage 16 embryonic body wall muscles labeled with Tropomyosin. *Mef2>ORF3a* embryos showed largely normal body wall musculature (see Fig. S1H for quantification). **G.** Apoptosis assay. *elav.Gal4* and *elav>ORF3a* adult brains labeled for cleaved Caspase-3 (green) and DAPI (blue). ORF3a induced Caspase-3 cleavage. **H.** Immunoblot of whole brain lysates from 3d *elav.Gal4* and *elav>ORF3a* adults validated results shown in (G). **I.** qRT-PCR of RNA from 3d old adult heads. Transcripts encoding IMD pathway reporters (*dipt* and *attA*) and a Toll pathway reporter (*Drs*) were enriched in *elav>ORF3a* flies. n>20 unless otherwise noted. Error bars represent standard error of the mean (SEM) from at least three independent replicates. Significance was determined by log-rank test (B), two-way ANOVA (C), and student’s t-test (I). *p < 0.05, **p < 0.01, ****p < 0.0001, (ns) non-significant.

**Figure S1. Related to Figure 1.**

**A.** Protein alignment of SARS-Cov-ORF3a and SARS-Cov-2-ORF3a. Dark blue shading shows identical residues, light blue shading shows similar residues. **B.** PCR of genomic DNA from ORF3a two independent transgenic lines. ORF3a band is indicated with red arrow. **C.** RT-PCR of ORF3a mRNA shows ORF3a expression is induced in muscle (*Mef2.Gal4*) and in the nervous system (*GMR.Gal4*). ORF3a band is shown (red arrow). **D.** Representative result of a climbing assay. *elav>ORF3a* flies (right) had reduced motor function. **E.** 6d old female flies. *elav>ORF3a* flies (right) showed severely swollen abdomens. **F.** Survival curves of *Mef2.Gal4* (control) and *Mef2>ORF3a* adult flies. *Mef2>ORF3a* median
lifespan was not significantly different than controls. n>60 flies per genotype. **G.** Longitudinal study of climbing ability. Locomotor activity was unaffected in Mef2>ORF3a flies. Each data point represents percent of flies that climbed above 5 cm, averaged for 3 independent trials. **H.** Quantification of embryonic body wall muscle phenotypes from Fig. 1F. Diagram shows the 30 muscles per embryonic segment; blue muscles were 100% normal in >60 Mef2>ORF3a embryonic segments, red muscles showed a developmental phenotype in at least 1 of the 60 segments. Dot plot shows frequency of muscle phenotypes is <9.0%. (ns) not significant.

**Figure 2. Chloroquine (CQ) protects against ORF3a-induced dysfunction.**

**A.** Survival curves of elav.Gal4 (control), elav>ORF3a, and CQ treated elav>ORF3a adult flies. CQ treatment significantly extended elav>ORF3a median lifespan. n>60 flies per genotype. **B.** Longitudinal study of climbing ability. Locomotor activity was significantly improved in elav>ORF3a flies treated with CQ. Each data point represents percent of flies that climbed above 5 cm, averaged for 3 independent trials. **C.** F₁ adult progeny treated with CQ from elav.gal4,Sb/Tb X UAS-ORF3a/Sb F₀ parents. 3 phenotypic classes with an equivalent number of progeny (33.3%) were expected. CQ treatment improved elav>ORF3a survivability to adulthood (compare to Fig. 1D). **D.** Immunoblot of whole brain lysates from 3d elav.Gal4, elav>ORF3a, and CQ treated elav>ORF3a adults. CQ reduced cleaved Caspase-3 levels in elav>ORF3a flies. **E,F.** qRT-PCR of RNA from 3d old adult heads. CQ treatment blunted the expression of the Toll pathway reporter Drs (E), but not IMD pathway reporters (dipt and attA; F) in elav>ORF3a flies. **G.** Live imaging of HELA cells transfected with CMV-GFP-ORF3a (green) for 24hr, treated with or without CQ, and labeled with Lysotracker (red). ORF3a transfected cells showed reduced Lysotracker staining (deacidified lysosomes) than untransfected controls (outlined in heat map). CQ treatment restored Lysotracker staining in ORF3a expressing cells (H). n>20 unless otherwise noted. Error bars represent standard error of the mean (SEM) from at least three independent replicates. Significance was determined by log-rank test (A), two-way ANOVA (B), and student’s t-test (H). *p < 0.05, **p < 0.01, ****p < 0.0001, (ns) non-significant.
Figure 1 ORF3a is pathogenic in nervous system

A

B

C

D

E

F

G

H

I

**Note:** ORF3a is pathogenic in nervous system. The graph shows the survival rates and climbing behavior of flies expressing ORF3a. The bar chart in panel C illustrates the climbing percentage over days post eclosion for different genotypes. Panel D presents a pie chart depicting the distribution of genotypes among the population.

**Figure Legends:**
- Panel A: Fluorescence microscopy images showing the expression of ORF3a and DAPI in the nervous system.
- Panel B: Graph showing the survival rate over days post eclosion.
- Panel C: Bar chart comparing climbing behavior with different genotypes.
- Panel D: Pie chart showing the distribution of genotypes.
- Panel E: Images depicting the effects of ORF3a on GMR tissues.
- Panel F: Images of the nervous system showing differences between Mef2+ and Mef2.ORF3a genotypes.
- Panel G: Fluorescence microscopy images of C-Caspase-3 expression in the nervous system.
- Panel H: Diagram illustrating the expression of C-Caspase-3 and β-tubulin.
- Panel I: Bar chart showing the expression levels of various genes.

**Copyright:** CC-BY-NC-ND 4.0 International license.
Supplemental Figure 1, related to Figure 1

**A** Sequence identity: 72.36%, sequence similarity: 90.2%

<table>
<thead>
<tr>
<th>Sars-Cov</th>
<th>Mef2.+</th>
<th>Mef2.ORF3a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consensus</td>
<td>mdifer ft t i a p v atatip qa6pgrgl</td>
<td>gva lavfgsa kil l krqlal kg f nillirtv yshillvaag</td>
</tr>
<tr>
<td>Sars-Cov</td>
<td>Mef2.+</td>
<td>Mef2.ORF3a</td>
</tr>
<tr>
<td>Consensus</td>
<td>ca fllylal yilq in rimz wcwhc skpllydanf cwhb ydscipynv t iv t ggd p dyqlbgv c sgkdi</td>
<td></td>
</tr>
</tbody>
</table>

---

**B**

![Image of gel electrophoresis](image)

**C**

![Image of gel electrophoresis](image)

**D**

![Image of gel electrophoresis](image)

**E**

![Image of elav. + elav.ORF3A](image)

**F**

![Graph of survival](image)

**G**

![Graph of climbing](image)

**H**

![Diagram of Mef2. + Mef2.ORF3a](image)
Figure 2 Chloroquine protects against ORF3a induced dysfunction

A. Survival graph showing the percentage of survival over days post eclosion for control (con+CQ), elav.ORF3a, and elav.ORF3a+CQ conditions.

B. Climbing percentage graph showing the percentage of climbing in control and CQ conditions across days.

C. Pie chart showing survival rates for ORF3a/Tb, elav.ORF3a, Sb/Tb, and control conditions.

D. Western blot images for C-Caspase-3 and β-tubulin with bands indicating expression levels.

E. Quantification of ORF3a mRNA expression levels in control and CQ conditions.

F. Gene expression analysis showing dipt and attA mRNA levels in control and CQ conditions.

G. Fluorescence images showing Merge, GFP-ORF3a, LysoTracker, and Heatmap for pCMV-GFP-ORF3a and pCMV-GFP-ORF3a+CQ.

H. Heatmap showing LysoTracker Red DND-99 normalized fluorescent intensity for pCMV-GFP-ORF3a and pCMV-GFP-ORF3a+CQ.

I. Diagram illustrating the process of infection, unhealthy cell, and apoptosis with CQ treatment.

J. Diagram showing the clinical recovery and full recovery phases with acute phase, post viral syndrome phase, viral protein in CNS, and virus in lung.

License: CC-BY-NC-ND 4.0 International license